PixCell Medical

Portable Medical Diagnostic Products for Point-of-care Testing

Health Tech & Life Sciences
Acquired by Soulbrain Holdings on May, 2021

Company Overview

Snapshot

Founded in June 2008 by Avishay Bransky, PixCell Medical operates with 51–200 employees. The company raised a total of $7.5M across 6 funding rounds from 2 investors. In May 2021, PixCell Medical was acquired by Soulbrain Holdings.

Business overview

PixCell Medical develops portable medical diagnostic products for point-of-care testing, focusing on complete blood count (CBC) tests. Its core product, the HemoScreen hematology analyzer, provides lab-quality precision with a small, simple diagnostic device, delivering fast and accurate analysis for five-part differential CBC tests from a single drop of blood within six minutes. The HemoScreen provides insights on 20 standard blood count parameters and comprehensive abnormal cell flagging. Utilizing patented Viscoelastic Focusing technology and AI-powered machine-vision technology, PixCell Medical aims to improve accessibility to CBC testing, reduce diagnostic turnaround time, and enable earlier detection of complex diseases such as leukemia, lymphoma, and other cancers and infections. The company serves markets globally, including the United States, Europe, Australia, and Asia, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Digital Healthcare.

Strategic signal

In September 2022, PixCell Medical partnered with Insight Medical to distribute its HemoScreen hematology point-of-care analyzer in Papua New Guinea. This partnership signifies the company's continued expansion into new geographic markets, demonstrating the global applicability and demand for its portable diagnostic solutions. For investors, this indicates a strategic focus on broadening market reach and increasing product adoption in underserved regions, potentially driving future revenue growth and solidifying its position in the point-of-care diagnostics market.

Company Intelligence Q&A

When was PixCell Medical acquired?
PixCell Medical was acquired by Soulbrain Holdings in May 2021.
What was a significant recent partnership for PixCell Medical?
In September 2022, PixCell Medical partnered with Insight Medical to distribute its HemoScreen hematology point-of-care analyzer in Papua New Guinea.
Did PixCell Medical receive any grants in 2022?
In February 2022, PixCell Medical was awarded a grant by the International Health-Tech Pilot Program.
What was the outcome of a clinical evaluation of PixCell Medical's HemoScreen in December 2022?
A clinical evaluation in December 2022 concluded that PixCell Medical's HemoScreen is an accurate and easy-to-use point-of-care analyzer for psychiatric companion diagnostics.
What was a key finding from a peer-reviewed study involving HemoScreen in October 2020?
A new peer-reviewed study in October 2020 demonstrated the ability of HemoScreen for rapid evaluation of acute leukemia patients.

External links